FGEN Relative Valuation
FGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FGEN is overvalued; if below, it's undervalued.
Historical Valuation
FibroGen Inc (FGEN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.49. The fair price of FibroGen Inc (FGEN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：8.12
Fair
-0.49
PE
1Y
3Y
5Y
Trailing
Forward
0.68
EV/EBITDA
FibroGen Inc. (FGEN) has a current EV/EBITDA of 0.68. The 5-year average EV/EBITDA is -5.11. The thresholds are as follows: Strongly Undervalued below -29.38, Undervalued between -29.38 and -17.25, Fairly Valued between 7.03 and -17.25, Overvalued between 7.03 and 19.16, and Strongly Overvalued above 19.16. The current Forward EV/EBITDA of 0.68 falls within the Historic Trend Line -Fairly Valued range.
0.66
EV/EBIT
FibroGen Inc. (FGEN) has a current EV/EBIT of 0.66. The 5-year average EV/EBIT is -4.08. The thresholds are as follows: Strongly Undervalued below -15.30, Undervalued between -15.30 and -9.69, Fairly Valued between 1.52 and -9.69, Overvalued between 1.52 and 7.13, and Strongly Overvalued above 7.13. The current Forward EV/EBIT of 0.66 falls within the Historic Trend Line -Fairly Valued range.
5.25
PS
FibroGen Inc. (FGEN) has a current PS of 5.25. The 5-year average PS is 5.45. The thresholds are as follows: Strongly Undervalued below -3.82, Undervalued between -3.82 and 0.82, Fairly Valued between 10.09 and 0.82, Overvalued between 10.09 and 14.73, and Strongly Overvalued above 14.73. The current Forward PS of 5.25 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
FibroGen Inc. (FGEN) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.24. The thresholds are as follows: Strongly Undervalued below -20.53, Undervalued between -20.53 and -11.88, Fairly Valued between 5.41 and -11.88, Overvalued between 5.41 and 14.05, and Strongly Overvalued above 14.05. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
FibroGen Inc. (FGEN) has a current P/FCF of 0.00. The 5-year average P/FCF is -9.03. The thresholds are as follows: Strongly Undervalued below -52.63, Undervalued between -52.63 and -30.83, Fairly Valued between 12.76 and -30.83, Overvalued between 12.76 and 34.56, and Strongly Overvalued above 34.56. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
FibroGen Inc (FGEN) has a current Price-to-Book (P/B) ratio of -1.93. Compared to its 3-year average P/B ratio of -9.52 , the current P/B ratio is approximately -79.75% higher. Relative to its 5-year average P/B ratio of -1.20, the current P/B ratio is about 60.27% higher. FibroGen Inc (FGEN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -243.64%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -147.24% , the current FCF yield is about -100.00% lower.
-1.96
P/B
Median3y
-9.52
Median5y
-1.20
-52.03
FCF Yield
Median3y
-243.64
Median5y
-147.24
Competitors Valuation Multiple
The average P/S ratio for FGEN's competitors is 0.00, providing a benchmark for relative valuation. FibroGen Inc Corp (FGEN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 774.80%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of FGEN decreased by 37.68% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 123.00K to 1.08M.
The secondary factor is the Margin Expansion, contributed -96.89%to the performance.
Overall, the performance of FGEN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is FibroGen Inc (FGEN) currently overvalued or undervalued?
What is FibroGen Inc (FGEN) fair value?
How does FGEN's valuation metrics compare to the industry average?
What is the current P/B ratio for FibroGen Inc (FGEN) as of Dec 05 2025?
What is the current FCF Yield for FibroGen Inc (FGEN) as of Dec 05 2025?
What is the current Forward P/E ratio for FibroGen Inc (FGEN) as of Dec 05 2025?